The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

INTRODUCTION: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ujjani, Chaitra, Mato, Anthony, Hill, Brian T, Allan, John N, Lansigan, Frederick, Jacobs, Ryan, Skarbnik, Alan, Tuncer, Hande, Pagel, John, Brander, Danielle, Cheson, Bruce, Barr, Paul, Roeker, Lindsey E, Pu, Jeffrey, Shah, Nirav N, Goy, Andre, Schuster, Stephen J, Lamanna, Nicole, Sehgal, Alison, Tam, Constantine S, Shadman, Mazyar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473982/
https://www.ncbi.nlm.nih.gov/pubmed/32943973
http://dx.doi.org/10.2147/BLCTT.S262592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473982/
https://www.ncbi.nlm.nih.gov/pubmed/32943973
http://dx.doi.org/10.2147/BLCTT.S262592

Ejemplares similares